Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

about

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

Item

http://www.wikidata.org/entity/Q50116255

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@en

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@nl

type

Item

label

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@en

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@nl

prefLabel

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@en

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@nl

P1476

Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.

@en

P2093

Brian Westbrook

http://www.w3.org/2001/XMLSchema#string

Robert M Conry

http://www.w3.org/2001/XMLSchema#string

Svetlana McKee

http://www.w3.org/2001/XMLSchema#string

Timothy Graham Norwood

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Pembrolizumab

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

PKR; a sentinel kinase for cellular stress

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.

Diagnosis of genital herpes simplex virus infection in the clinical laboratory

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1

P304

839-846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/21645515.2017.1412896

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29420123

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

Añaw

P932

5893211

http://www.w3.org/2001/XMLSchema#string